" Citing a lack of cardiovascular benefit, the FDA is taking the unusual step of withdrawing approvals it had previously given for use of niacin and fenofibric acid with statins to treat high cholesterol.
The decision affects niac"...
The most common adverse reactions associated with Infasurf dosing procedures in the controlled trials were cyanosis (65%), airway obstruction (39%), bradycardia (34%), reflux of surfactant into the endotracheal tube (21%), requirement for manual ventilation (16%), and reintubation (3%). These events were generally transient and not associated with serious complications or death. The incidence of common complications of prematurity and RDS in the four controlled Infasurf trials are presented in Table 3. Prophylaxis and treatment study results for each surfactant are combined.
Table 3 : Common Complications of Prematurity and RDS
in Controlled Trials
|Patent ductus arteriosus||47||48||45||48|
|Severe intracranial hemorrhagea||12||10||9||7|
|IVH and PVL b||7||3||5||5|
|Pulmonary air leaks||12||22||15||15|
|Pulmonary interstitial emphysema||7||17||10||10|
|a Grade III and IV by the method of Papile.
b Patients with both intraventricular hemorrhage and periventricular leukomalacia.
Two-year follow-up data of neurodevelopmental outcomes in 415 infants enrolled in 5 centers that participated in the Infasurf vs. Exosurf Neonatal® controlled trials demonstrated significant developmental delays in equal percentages of Infasurf and Exosurf Neonatal® patients.
Read the Infasurf (calfactant) Side Effects Center for a complete guide to possible side effects
No Information ProvidedThis monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 7/12/2016
Additional Infasurf Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.